



LINK PHARMA CHEM LTD.

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2018

SR. NO.	PARTICULARS	(RS. IN LAKHS)					
		Quarter ended			Nine Month Ended		Year ended on
		31.12.2018 Un-Audited	30.09.2018 Un-Audited	31.12.2017 Un-Audited	31.12.2018 Un-Audited	31.12.2017 Un-Audited	31.03.2018 Audited
1	Income						
	[a] Revenue from Operation	607.98	819.27	635.12	1,975.91	1,875.08	2,396.44
	[b] Other Income	6.13	-6.71	0.04	8.05	0.04	6.95
	Total Income 1(a+b)	614.12	812.56	635.16	1,983.96	1,875.12	2,403.39
2	Expenses						
	Cost of Materials consumed	436.31	381.17	236.32	1,142.91	590.21	782.94
	Change in Inventories of finished goods work in progress	(151.37)	76.27	(41.44)	(89.02)	190.55	206.73
	Excise duty	-	-	-	-	41.50	43.21
	Employee benefit expenses	79.88	86.55	110.92	232.68	233.51	489.78
	Finance Costs	8.38	9.10	10.03	26.37	35.47	61.56
	Depreciation and amortisation expenses	21.55	21.55	20.73	64.58	62.17	85.95
	Other expenditure	152.89	178.43	224.00	453.99	591.61	596.17
	Total Expenses	547.64	753.06	560.56	1,831.51	1,745.02	2,266.34
3	Profit before tax (1-2)	66.48	59.50	74.60	152.45	130.10	137.05
4	Tax expenses						
	Current Tax	14.56	13.04	13.82	32.70	24.40	27.56
	MAT Credit Recognised	-	-	-	-	-	(39.53)
	Deferred Tax	-	-	-	-	-	35.54
5	Profit for the year (3-4)	51.92	46.45	60.78	119.75	105.70	113.48
6	Other Comprehensive Income (Net of Tax)						
	Items that will not be reclassified to Profit or Loss	2.12	4.25	-	6.37	-	7.14
	Income tax effect of the above	(0.41)	(0.82)	-	(1.23)	-	(1.95)
	Total Comprehensive Income for the period	1.71	3.43	-	5.14	-	5.19
7	(Net of Tax) (5+6)	53.64	49.88	60.78	124.90	105.70	118.67
8	Paid up Equity share capital	444.05	444.05	444.05	444.05	444.05	444.05
	(Face Value of each share of Rs. 10/- each)						
9	Reserves excluding Revaluation Reserve as per balance sheet of previous year	-	-	-	-	-	534.89
10	Earnings Per Share						
	Basic and diluted (in Rs.)	1.21	1.12	1.37	2.81	2.38	2.56

Notes :

- These Financial Results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meeting held on 28th January, 2019. The Statutory Auditors have carried out the limited review.
- The Company's operation fall under single segment namely "Chemicals" for the purpose of Indian Accounting standard (Ind As 108) on Segment Reporting.
- Consequent to implementation of the Goods and Service Tax (GST) with effect from July 1, 2017, presentation of revenue for the quarters after that date excludes GST and not comparable with prior periods which includes Excise Duty.

PLACE: Vadodara
DATE : 28.01.2019



For and behalf of the Board of
Link Pharma Chem Ltd.

S. G. Thakur
S. G. Thakur
Managing Director